In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses

Keykavous Parang, Leonard I. Wiebe, Edward E. Knaus, Jyy Shiang Huang, David L. Tyrrell, Ferenc Csizmadia

Research output: Contribution to journalArticle

Abstract

A group of myristic acid analogs, designed as alternative substrates for N-myristoyltransferase (MT), were evaluated against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) in vitro. Antiviral potency was increased when S or O was substituted for -CH2- in myristic acid and selectivity was affected by the presence and position of the heteroatoms and phenyl groups. A correlation was established among anti-HIV activity, Log P and Log D7.4 and between anti-HIV activity and carbonyl-heteroatom interatomic distances in the myristoyl analogs. 12-Thioethyldodecanoic acid 6 was moderately active (EC50 = 9.37 μM) against HIV-infected T4-lymphocytes (CEM-SS cell line), and it exhibited in vitro activity (EC50 = 17.8 μM) against HBV-producing 2.2.15 cell cultures derived from a human hepatoblastoma cell line (Hep G2). 12-Methoxydodecanoic acid 1 exhibited in vitro activity (EC50 = 20-30 μM) against hepatitis B in the HBV DNA-transfected 2.2.15 cell line. At a concentration of 10 μg/ml, none of the fatty acids significantly inhibited the replication of DHBV in infected hepatocytes.

Original languageEnglish (US)
Pages (from-to)75-90
Number of pages16
JournalAntiviral Research
Volume34
Issue number3
DOIs
StatePublished - May 1997
Externally publishedYes

Fingerprint

Myristic Acid
Hepatitis B virus
Antiviral Agents
Duck Hepatitis B Viruses
HIV
CD4-Positive T-Lymphocytes
Cell Line
Acids
Hep G2 Cells
Hepatitis B
Hepatocytes
Fatty Acids
Cell Culture Techniques
In Vitro Techniques
DNA

Keywords

  • DHBV
  • HBV
  • HIV
  • Myristic acid analogs

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses. / Parang, Keykavous; Wiebe, Leonard I.; Knaus, Edward E.; Huang, Jyy Shiang; Tyrrell, David L.; Csizmadia, Ferenc.

In: Antiviral Research, Vol. 34, No. 3, 05.1997, p. 75-90.

Research output: Contribution to journalArticle

Parang, Keykavous ; Wiebe, Leonard I. ; Knaus, Edward E. ; Huang, Jyy Shiang ; Tyrrell, David L. ; Csizmadia, Ferenc. / In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses. In: Antiviral Research. 1997 ; Vol. 34, No. 3. pp. 75-90.
@article{8dead8c7ed16417781a4bca67cf96dc0,
title = "In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses",
abstract = "A group of myristic acid analogs, designed as alternative substrates for N-myristoyltransferase (MT), were evaluated against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) in vitro. Antiviral potency was increased when S or O was substituted for -CH2- in myristic acid and selectivity was affected by the presence and position of the heteroatoms and phenyl groups. A correlation was established among anti-HIV activity, Log P and Log D7.4 and between anti-HIV activity and carbonyl-heteroatom interatomic distances in the myristoyl analogs. 12-Thioethyldodecanoic acid 6 was moderately active (EC50 = 9.37 μM) against HIV-infected T4-lymphocytes (CEM-SS cell line), and it exhibited in vitro activity (EC50 = 17.8 μM) against HBV-producing 2.2.15 cell cultures derived from a human hepatoblastoma cell line (Hep G2). 12-Methoxydodecanoic acid 1 exhibited in vitro activity (EC50 = 20-30 μM) against hepatitis B in the HBV DNA-transfected 2.2.15 cell line. At a concentration of 10 μg/ml, none of the fatty acids significantly inhibited the replication of DHBV in infected hepatocytes.",
keywords = "DHBV, HBV, HIV, Myristic acid analogs",
author = "Keykavous Parang and Wiebe, {Leonard I.} and Knaus, {Edward E.} and Huang, {Jyy Shiang} and Tyrrell, {David L.} and Ferenc Csizmadia",
year = "1997",
month = "5",
doi = "10.1016/S0166-3542(96)01022-4",
language = "English (US)",
volume = "34",
pages = "75--90",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses

AU - Parang, Keykavous

AU - Wiebe, Leonard I.

AU - Knaus, Edward E.

AU - Huang, Jyy Shiang

AU - Tyrrell, David L.

AU - Csizmadia, Ferenc

PY - 1997/5

Y1 - 1997/5

N2 - A group of myristic acid analogs, designed as alternative substrates for N-myristoyltransferase (MT), were evaluated against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) in vitro. Antiviral potency was increased when S or O was substituted for -CH2- in myristic acid and selectivity was affected by the presence and position of the heteroatoms and phenyl groups. A correlation was established among anti-HIV activity, Log P and Log D7.4 and between anti-HIV activity and carbonyl-heteroatom interatomic distances in the myristoyl analogs. 12-Thioethyldodecanoic acid 6 was moderately active (EC50 = 9.37 μM) against HIV-infected T4-lymphocytes (CEM-SS cell line), and it exhibited in vitro activity (EC50 = 17.8 μM) against HBV-producing 2.2.15 cell cultures derived from a human hepatoblastoma cell line (Hep G2). 12-Methoxydodecanoic acid 1 exhibited in vitro activity (EC50 = 20-30 μM) against hepatitis B in the HBV DNA-transfected 2.2.15 cell line. At a concentration of 10 μg/ml, none of the fatty acids significantly inhibited the replication of DHBV in infected hepatocytes.

AB - A group of myristic acid analogs, designed as alternative substrates for N-myristoyltransferase (MT), were evaluated against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) in vitro. Antiviral potency was increased when S or O was substituted for -CH2- in myristic acid and selectivity was affected by the presence and position of the heteroatoms and phenyl groups. A correlation was established among anti-HIV activity, Log P and Log D7.4 and between anti-HIV activity and carbonyl-heteroatom interatomic distances in the myristoyl analogs. 12-Thioethyldodecanoic acid 6 was moderately active (EC50 = 9.37 μM) against HIV-infected T4-lymphocytes (CEM-SS cell line), and it exhibited in vitro activity (EC50 = 17.8 μM) against HBV-producing 2.2.15 cell cultures derived from a human hepatoblastoma cell line (Hep G2). 12-Methoxydodecanoic acid 1 exhibited in vitro activity (EC50 = 20-30 μM) against hepatitis B in the HBV DNA-transfected 2.2.15 cell line. At a concentration of 10 μg/ml, none of the fatty acids significantly inhibited the replication of DHBV in infected hepatocytes.

KW - DHBV

KW - HBV

KW - HIV

KW - Myristic acid analogs

UR - http://www.scopus.com/inward/record.url?scp=0030961732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030961732&partnerID=8YFLogxK

U2 - 10.1016/S0166-3542(96)01022-4

DO - 10.1016/S0166-3542(96)01022-4

M3 - Article

C2 - 9191015

AN - SCOPUS:0030961732

VL - 34

SP - 75

EP - 90

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -